TY - JOUR
T1 - Mesenchymal stem cells for the treatment of idiopathic pulmonary fibrosis
AU - Tzouvelekis, Argyrios
AU - Toonkel, Rebecca
AU - Karampitsakos, Theodoros
AU - Medapalli, Kantha
AU - Ninou, Ioanna
AU - Aidinis, Vasilis
AU - Bouros, Demosthenes
AU - Glassberg, Marilyn K.
N1 - Publisher Copyright:
© 2018 Tzouvelekis, Toonkel, Karampitsakos, Medapalli, Ninou, Aidinis, Bouros and Glassberg.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive lung disease of unknown origin. Prognosis is poor, with limited treatment options available, and the median survival remains just 3-5 years. Despite the use of pirfenidone and nintedanib for the treatment of IPF, curative therapies remain elusive and mortality remains high. Regenerative medicine and the use of cell-based therapies has recently emerged as a potential option for various diseases. Promising results of preclinical studies using mesenchymal stem cells (MSCs) suggest that they may represent a potential therapeutic option for the treatment of chronic lung diseases including IPF. Encouraging results of Phase 1 studies of MSCs various have reduced safety concerns. Nonetheless, there is still a pressing need for exploratory biomarkers and interval end-points in the context of MSCs investigation. This review intends to summarize the current state of knowledge for stem cells in the experimental and clinical setting of IPF, present important safety and efficacy issues, highlight future challenges and address the need for large, multicenter clinical trials coupled with realistic end-points, including biomarkers, to assess treatment efficacy.
AB - Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive lung disease of unknown origin. Prognosis is poor, with limited treatment options available, and the median survival remains just 3-5 years. Despite the use of pirfenidone and nintedanib for the treatment of IPF, curative therapies remain elusive and mortality remains high. Regenerative medicine and the use of cell-based therapies has recently emerged as a potential option for various diseases. Promising results of preclinical studies using mesenchymal stem cells (MSCs) suggest that they may represent a potential therapeutic option for the treatment of chronic lung diseases including IPF. Encouraging results of Phase 1 studies of MSCs various have reduced safety concerns. Nonetheless, there is still a pressing need for exploratory biomarkers and interval end-points in the context of MSCs investigation. This review intends to summarize the current state of knowledge for stem cells in the experimental and clinical setting of IPF, present important safety and efficacy issues, highlight future challenges and address the need for large, multicenter clinical trials coupled with realistic end-points, including biomarkers, to assess treatment efficacy.
KW - Efficacy
KW - Idiopathic pulmonary fibrosis
KW - Mesenchymal stem cells
KW - Safety
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85050117447&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050117447&partnerID=8YFLogxK
U2 - 10.3389/fmed.2018.00142
DO - 10.3389/fmed.2018.00142
M3 - Review article
AN - SCOPUS:85050117447
SN - 2296-858X
VL - 5
JO - Frontiers in Medicine
JF - Frontiers in Medicine
IS - MAY
M1 - 142
ER -